International meeting "immunotherapy of cancer: Challenges and needs"

Cancer Immunology, Immunotherapy

Volumn 56, Issue 4, 2007, Pages 581-585

  Ferrantini, Maria ^a   Capone, Imerio ^a   Marincola, Francesco M ^b   Parmiani, Giorgio ^c   Belardelli, Filippo ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cancer; Immunotherapy; Vaccines

Indexed keywords

ABATACEPT; ALPHA INTERFERON; CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; DACARBAZINE; IMIQUIMOD; MELAN A;

ADOPTIVE IMMUNOTHERAPY; CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; DENDRITIC CELL; HEALTH CARE ORGANIZATION; HEALTH PROMOTION; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PUBLIC HEALTH; T LYMPHOCYTE ACTIVATION;

ANIMALS; CLINICAL TRIALS; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 33846810204     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-006-0251-6     Document Type: Conference Paper

References (10)

1. van Hall T, Wolpert EZ, van Veelen P et al (2006) Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med 12:417-424
2. Loukinov D, Ghochikyan A, Mkrtichyan M et al (2006) Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. J Cell Biochem 98:1037-1043
3. Bronte V, Zanovello P (2005) Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 5:641-654
4. Taieb J, Chaput N, Menard C et al (2006) A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 12:214-219
5. Speiser DE, Baumgaertner P, Barbey C et al (2006) A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination. J Immunol 177:1338-1348
6. Di Pucchio T, Pilla L, Capone I et al (2006) Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res 66:4943-4951
7. Gogas H, Ioannovich J, Dafni U et al (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354:709-718
8. Schadendorf D, Ugurel S, Schuler-Thurner B et al (2006) Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 17:563
9. + T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy. J Immunol 176:7726-7735
10. Hoos A, Parmiani G, Hege K et al (2006) A new clinical development paradigm for cancer vaccines and related biologics. J Immunother (in press)